Galapagos NV (NASDAQ:GLPG) has been given a consensus recommendation of “Buy” by the eleven ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $101.00.
GLPG has been the topic of several research analyst reports. Janney Montgomery Scott cut Galapagos NV from a “buy” rating to a “sell” rating in a research report on Monday, April 24th. Zacks Investment Research cut Galapagos NV from a “buy” rating to a “hold” rating in a research report on Monday, April 24th. Stifel Nicolaus lifted their price target on Galapagos NV from $65.00 to $83.00 and gave the company a “hold” rating in a research report on Monday, May 1st. TheStreet upgraded Galapagos NV from a “d+” rating to a “c” rating in a research report on Wednesday, May 17th. Finally, BTIG Research reiterated a “buy” rating and set a $98.00 price target on shares of Galapagos NV in a research report on Tuesday, June 20th.
Galapagos NV (NASDAQ GLPG) traded up 3.28% during midday trading on Monday, reaching $83.72. The company had a trading volume of 160,092 shares. The firm’s 50-day moving average price is $77.64 and its 200 day moving average price is $79.02. Galapagos NV has a 12 month low of $52.50 and a 12 month high of $94.88. The firm’s market capitalization is $4.26 billion.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Stevens Capital Management LP acquired a new position in shares of Galapagos NV during the second quarter worth $292,000. Dorsey Wright & Associates acquired a new position in shares of Galapagos NV during the second quarter worth $1,151,000. FNY Partners Fund LP increased its position in shares of Galapagos NV by 1,218.2% in the second quarter. FNY Partners Fund LP now owns 14,500 shares of the biotechnology company’s stock worth $1,109,000 after buying an additional 13,400 shares in the last quarter. Pacad Investment Ltd. acquired a new position in shares of Galapagos NV during the second quarter worth $168,000. Finally, Airain ltd increased its position in shares of Galapagos NV by 343.9% in the second quarter. Airain ltd now owns 12,204 shares of the biotechnology company’s stock worth $934,000 after buying an additional 9,455 shares in the last quarter. Institutional investors and hedge funds own 19.99% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://stocknewstimes.com/2017/08/19/galapagos-nv-nasdaqglpg-receives-average-recommendation-of-buy-from-analysts-updated-updated-updated.html.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.
